Drugs / MEDI8852
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02350751 | Jan → Jun 2015 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02603952 | Dec 2015 → Dec 2016 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03903718 | Apr → Oct 2020 | influenza | MedImmune LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT03028909 | Jul 2017 → Jul 2019 | — | MedImmune LLC | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI8852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03028909 ↗ |
| Known as | Pan-influenza a mab medi8852 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298034 ↗ |
| Modality | Monoclonal antibody | “MEDI8852 is an IgG1 kappa monoclonal antibody” PMID 28844541 ↗ Aug 2017 |
| Route | Intravenous | “Investigational product will be delivered intravenously (IV).” NCT02350751 ↗ |